We developed a human inhibition monoclonal enzyme-linked immunosorbent assay (HIMELISA) to investigate the human immune response to the lipooligosaccharides (LOS) of Neisseria meningitidis. Monoclonal antibodies (MAb) were used to define seven epitopes on four LOS molecules of a meningococcal strain (126E) previously shown to express immunogenic LOS epitopes. The assay could distinguish epitope-specific antibody within whole sera. Neither the specificity nor the amount of the antibody measured by HIMELISA in sera of vaccinates changed during the immune response to meningococcal capsular polysaccharides, a chemically unrelated antigen. By using the HIMELISA, it was determined that sera from adults convalescing from meningococcal disease strongly inhibited MAb binding to two of the seven defined epitopes. The 3.6-kilodalton LOS of strain 126E expressed both of these epitopes. In addition, one of the inhibited epitopes was also expressed on the 4.0-kilodalton LOS of strain 126E. The convalescent-phase sera inhibited MAb binding to these two epitopes when they were expressed on LOS of diverse meningococcal strains. An acute-phase serum blocked MAb to the two epitopes to a lesser degree than did a convalescent-phase serum from the same patient. Immunoblotting the sodium dodecyl sulfate-polyacrylamide gel electrophoresisseparated LOS with convalescent-phase sera confirmed the specificity of the human anti-LOS antibody identified by HIMELISA.
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Considerable progress has been made in characterizing surface antigens of Neisseria meningitidis that are involved in various immunologic processes and in relating the manifestations of meningococcal disease to failures of immune effector mechanisms (9, 10, 13) . We do not know, however, how to immunologically protect children younger than 2 years of age. Since capsular antibody is naturally acquired very slowly during infancy (29) and polysaccharide vaccines are either nonimmunogenic or poorly so in children younger than 2 years of age (8, 12, 22, 29, 30) , alternative subcapsular immunogens that would induce broadly reactive bactericidal antibody in this age group have been sought. This study focuses on the immunogenicity of the lipooligosaccharides (LOS) present in the outer membrane complex of the meningococcus.
Young children can make antibody to meningococcal LOS. In a study of infants and children recovering from meningococcal disease, Griffiss et al. (12) determined that the purified LOS from an N. meningitidis group C strain (126E) was able to inhibit bactericidal activity in sera from children convalescing from group B disease, regardless of the outer membrane protein or LOS serotype of the infecting strain.
Neisseria spp. make from one to six different LOS molecules, with relative molecular weights (Mrs) of 3,200 to 7, 100 , that can be characterized by electrophoretic mobility demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (24, 26, 28, 35, 39) . Differences in mobility appear to be due to heterogeneity of oligosaccha-* Corresponding author. t Paper no. 31 from the Centre for Immunochemistry.
ride chemical composition (16) . These LOS are glycolipids that contain three domains: a basal oligosaccharide composed of 2-keto-3-deoxyoctulosonate (dOclA), heptose, and hexosamines; a segment of variable length that is composed of glucose or galactose; and a terminal polylactosamine structure that mimics those of human glycosphingolipids (17, (19) (20) (21) . Serotypic diversity resides in differences in the composition of the basal oligosaccharide and the length of the intervening segment (17, 25) . The LOS produced by a neisserial strain varies over growth time; stationary-phase organisms have LOS of higher molecular weight than do organisms in exponential phase (1, 31) . This variation may be related to the capping or completion of the LOS molecule.
N. meningitidis 126E fails to cap its LOS with the polylactosamine terminus, thus exposing more basal structures and their epitopes (17, 23 (24, 26, 28, 35, 39) (35) .
LOS. LOS were extracted from acetone-dried organisms by the hot phenol-water method (34, 40) .
Sera. Sera previously collected from adults convalescing from disseminated meningococcal disease were studied.
They had been stored frozen at -20°C. (41) . Fifteen MAbs bound to strain 126E LOS and were characterized for this study.
Purified LOS from strains 126E, M978, 7883, and 8032 were separated by SDS-PAGE by using a modification of the method of Laemmli (33, 35) . Briefly, LOS were diluted in a buffer consisting of 2% SDS in 60 mM Tris hydrochloride, 1.0 mM EDTA, 3.5% 2-mercaptoethanol, 18% glycerol, and 2% bromophenol blue and heated at 100°C for 5 min. The LOS samples (0.5 to 11.5 jig per well) were electrophoresed in duplicate discontinuous slab gels (3% acrylamide spacer gel; 12.9 to 13.1% resolving gel) at 10 mA per gel through the spacer gel and at 15 mA per gel through the resolving gel. The LOS bands were visualized by silver stain (38) . The Mrs of the LOS bands of strains M978, 7883, and 126E were estimated by comparing their migration distances with those of the six LOS bands of strain 8032 whose Mrs have been determined (24, 33, 35 We used an ELISA to determine the optimal concentrations of antigen (LOS) and MAb to be used for the HIMEL-ISA. A grid was constructed (26) by coating rows of wells with serial doubling dilutions of strain 126E LOS and testing each row with dilutions (50 ,ul) of MAb. The secondary antibody, Vectastain, and substrate steps were as described above for the HIMELISA. An antibody binding curve was generated by plotting absorbance against log2 dilution of the MAb for each LOS concentration. We chose from this curve an LOS concentration that resulted in absorbance that was 4 to 10 times background, but not in antigen excess, and a MAb concentration that was <60% of the saturation point for that concentration of LOS. The same LOS concentration was used for the HIMELISAs for all seven MAbs; the optimal concentration of each MAb was determined separately by grid titration.
Confirmation of inhibition by human sera of MAb-epitope binding. We used LOS made by strains 120M and M992 in HIMELISA to confirm the inhibition by human sera of MAb binding to its epitope. We based the choice of these two LOS on the MAbs they bound. As determined by ELISA, strain 120M LOS bound MAb D6A but not MAb 6B7 and strain M992 LOS bound MAb 6B7 but not MAb D6A. We used grid titration to determine optimal concentrations of LOS and MAb to be used in the HIMELISA.
Analysis of HIMELISA. For each serum-MAb HIMELISA with strain 126E LOS, we calculated the mean absorbance of the uninhibited control. We divided the replicate absorbances obtained at each serum dilution by this value. A simple linear regression with replication was performed for the linear portion of the curve for each MAb and serum by using log2 serum dilution versus absorbance divided by the mean of the control. P < 0.05 for a positive slope was considered significant inhibition. Curves with a mean percentage of control >98% at the highest serum concentration were considered negative and were not subjected to linear regression analysis.
The differences in absorbance among the duplicate wells at each serum dilution was '20% of the mean for nearly all HIMELISAs.
Immunoblots with convalescent-phase sera. Purified LOS from strains 126E, 7883, M978, and 8032 were separated by SDS-PAGE and transferred to nitrocellulose by using the 12 (23, 27) . No other type Li strains have been identified to our knowledge. Strain M978 is the L8 prototype strain (23, 27 of the four convalescent-phase sera and strain 126E LOS. Three of the sera were drawn from individuals ill with group C disease, and one was drawn from an individual with group B disease. The sera were obtained 7 to 12 days after the onset of illness. Only two MAbs, D6A and 6B7, were significantly inhibited by all four of the convalescent-phase sera (sera 1, 2, 3, and 4c) ( Table 2 ). MAb MN13H21 was inhibited by one of four sera (serum 4c), and MAb 3E2 was inhibited by one of four sera (serum 2). Log 2 Serum Dilution that were significantly inhibited. Binding of D6A was inhibited at least 70% by the highest concentration of each convalescent-phase serum. This level of inhibition was sustained for one log2 dilution in three of the sera and then decreased proportionately with serum dilution (Fig. 4A) . MAb 6B7 was 49 to 66% inhibited at the highest concentrations of sera, and this inhibition also decreased proportionately with serum dilution (Fig. 4B) . MAb 3E2 was inhibited to a lesser extent than D6A and 6B7 by serum 2 (Fig. 4C) . MAb MN13H21 was also inhibited to a lesser extent by serum 4c (Fig. 4D) . In Fig. 5 are shown, as examples, the results of the HIMELISA for three convalescent-phase sera (no. 1, 3, and 4c) and one acute serum (no. 4a) that were determined to be noninhibitory of the binding of MAb 3E2 to strain 126E LOS. Three MAbs (3C9, 1B5, and 3D4) were not inhibited by any of the four convalescent-phase sera. Determination of antibody in normal human sera that bound strain 126E LOS epitopes. We evaluated the performance of the HIMELISA by studying sera drawn from three colleagues before and 11 days after vaccination with tetravalent meningococcal polysaccharide vaccine. We analyzed MAbs D6A and 6B7 only. The prevaccination sera of all three subjects showed measurable antibody that inhibited binding of MAb D6A (Fig. 6 ). The quantity of this antibody did not increase in any of the three subjects during the demonstrated response to a different glycose antigen of (Fig. 7) . The antibodies that were able to bind to the 6B7-and D6A-defined epitopes expressed on strain 126E LOS were present in the acute-phase serum of the individual and increased either in quantity or affinity during the convalescent phase.
Ability of human convalescent-phase sera to inhibit MAb binding to epitopes on LOS from other meningococcal strains. To evaluate the reproducibility of the HIMELISA, we used LOS from two other meningococcal strains. Purified LOS from strain 120M expressed the D6A epitope but not the 6B7 (Fig. 9B) . In contrast, one serum (no. LOS (Fig. 9C) . The relatively high titer of the partial Log 2 Serum Dilution inhibition suggested that human antibody bound to only one Pecn .ihbtino. Mbbndn.ostrain 126E LOS by of the epitopes recognized by D6A on this LOS (17) .
Percent inhibition of MAb binding to
Immunoblot analysis of antibody in human convalescent-(day 1) versus convalescent-phase (day 7) sera drawn sera apale of anding in hules.convalescentividual infected with a group C meningococcus (Table 2 , phase sera capable of binding LOS molecules. We performed 4c). Curves show inhibition of binding of MAb D6A (A) an immunoblot with each convalescent-phase serum and B7 (B). 4a, Acute-phase serum; 4c, convalescent-phase SDS-PAGE-separated LOS from strains 126E, M978, 7883, aes for the duplicate wells are shown for acute-(*) and and 8032 (Fig. 10) . Table 1 126E, all LOS of M978 and 7883, and all LOS of 8032 except the four convalescent-phase sera. All four convathe 3,600-Mr LOS. All four convalescent-phase sera conase sera inhibited the binding of each MAb to its tained antibody to the 3,600-Mr LOS of strain 126E. This LOS (Fig. 8) .
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M978 [Mr, 4, 800] 4,200-Mr LOS of strain 126E. MAb 3D4, 1B5, and 3E2 all bound this LOS molecule. Table 2 shows that serum 1 did not inhibit these three MAbs as determined by HIMELISA.
DISCUSSION
In this study, we identified seven MAb-defined epitopes on meningococcal LOS, confirming the antigenic heterogeneity of these molecules that was previously shown. The HIMELISA permitted epitope-specific discrimination among LOS antibodies in whole sera and demonstration of their relationship to individual LOS molecules. Although adult vaccinates had measurable antibody specific for two of the epitopes, the levels of the antibody were higher than those in acute-phase serum and lower than those in convalescent-phase sera. Thus, the HIMELISA can provide useful information about the LOS epitope-specific composition of antibody in a serum, estimate changes in the levels of antibody, and detect the induction of antibody of new specificities, as shown for the MAb MN13H21-defined epitope in the convalescent-phase serum 4c.
Only two of the seven epitopes were strongly inhibited by human convalescent-phase sera. One of these (D6A) was expressed on both the 3,600-and 4,000-Mr LOS molecules of meningococcal strain 126E. The other epitope (6B7) was expressed on the 3,600-Mr LOS of strain 126E. Since the D6A-defined epitope was expressed on two LOS molecules of 126E of different Mrs, determining the relationship of this immunogenic epitope to the chemical structure of the LOS molecules on which it is expressed will be important in understanding the human immune response to meningococcal LOS.
When we investigated the expression of the D6A epitope on other meningococcal strains, we found that it was expressed on LOS of different Mrs depending on the strain of origin (Mr range, 3,200 to 5,400), but all strains that bound it made a 3,600-Mr LOS that expressed the epitope. Since this epitope was expressed on a molecule with as small an Mr as 3,200 (Table 1 , strain 8032), we conclude that it must be in a core region of the LOS molecule. Kim et al. (24) found that the epitope defined by D6A was highly conserved on N. meningitidis group A strains and was expressed on multiple LOS molecules of variable Mr. It was also expressed on some group B, C, and Y strains (24) .
The 6B7-defined epitope was restricted to the 3,600-Mr molecule of all meningococcal strains that we investigated. Dudas and Apicella (6) found that the 6B7-defined epitope was not expressed on the higher-molecular-weight (Mr, 4,700) parent LOS molecule of a gonococcal strain but was expressed on lower-molecular-weight LOS of pyocin-resistant strains (Mrs, 4,000 and 3,600, respectively). They concluded that it was a cryptic epitope that was exposed when sugar residues were removed from the parent LOS molecule. Our data are consistent with the concept that the two epitopes, D6A and 6B7, are most likely located in the core region of the LOS molecule. Because each convalescent-phase serum inhibited both the D6A-and the 6B7-defined epitopes, we were concerned that one antibody population was inhibiting both epitopes. We repeated the HIMELISA with the four convalescentphase sera with LOS from other meningococcal strains that by ELISA expressed either the D6A-defined epitope or the 6B7-defined epitope but not both. The convalescent-phase sera were able to inhibit both epitopes. Since the LOS of each organism in an unseparated state on solid phase did not express both epitopes, interference or blocking of one epitope by antibody binding to the other seemed unlikely. These results indicated that the sera contained two antibody populations, one recognizing the D6A epitope and one recognizing the 6B7 epitope.
We showed that these LOS epitopes were inhibited by human antibody regardless of the meningococcal strain of origin. However, we found that the degree of inhibition of an epitope was influenced by the strain of origin. This probably was a result of differences in affinity of the MAb and/or human antibody for the epitope expressed on different LOS molecules. Griffiss et al. also found that the affinity of a MAb binding to its epitope was dependent on the LOS repertoire of the strain of origin (17) . Interestingly, SDS-PAGE appeared to expose the 6B7 epitope on the LOS of strain 120M that was not apparent by ELISA. This demonstrated the influence of the physical state of LOS on epitope expression. If the LOS repertoire of a strain and the physical state of LOS strongly influence epitope expression, it becomes important to know the Mr of the molecule expressing that epitope. We were able to define antibody binding sites on meningococcal LOS by their MAb binding and the Mr of the molecule that expressed them. The HIMELISA was capable of identifying a potentially immunogenic epitope, but it could not differentiate LOS molecules when that epitope was expressed on molecules of different Mrs of a strain. To investigate whether the binding of human antibody to an epitope varied by the Mr of the LOS molecule on which it appeared, we tested the convalescent-phase sera for binding to the SDS-PAGE-separated LOS molecules of our test strains. These immunoblots identified human antibody to LOS molecules only, not to epitopes, so we compared the immunoblots with the binding patterns of the MAbs to the same LOS. The immunoblots were consistent with the results of the HIMELISA but were not helpful in identifying individual, immunogenic epitopes.
We conclude that the immunogenicity of an epitope may vary when expressed on LOS molecules of different Mrs, that the physical state of LOS influences epitope expression, and that the affinity of an antibody to its epitope is dependent on the Mr of the molecule on which the epitope is located, the strain of origin, and method of LOS presentation (SDS-PAGE versus solid-phase ELISA).
An LOS serotyping system for N. meningitidis strains that used hemagglutination and solid-phase radioimmunoassay inhibition was described previously (7, 27, 42, 43) . Strain 126E is type L1,8; it is the prototype Li strain. No other Li strains have been identified, so we do not know if any of our MAb-defined epitopes reflect the Li antigen. Strain 126E is also type L8, as is strain M978, which is the L8 prototype strain. Kim et al. (24) found that MAb 2-1-L8 was serotype specific for L8 and bound to a 3,600-Mr LOS. In our study, MAb MN13H21 bound the same pattern of LOS molecules as did MAb 2-1-L8 and may reflect the L8 antigen. Kim et al. also found that MAb 4C4 was Lii serotype specific. Strain 7883 is type Lii and makes a single LOS molecule of 3,600 Mr. We found that, although MAb 4C4 bound to strain 7883, it did not bind to strain 126E and so was not used in our inhibition studies.
Poolman et al. (31) found that MAb D6A was bactericidal for a group B meningococcal strain (2996). LOS molecules bearing epitopes that induce broadly reactive, bactericidal antibody in children could be incorporated into a meningococcal vaccine. We have identified two potential molecules, the 3,600-and 4,000-Mr LOS of N. meningitidis strain 126E, for this use. The techniques described in this study will be used to investigate the immune response to neisserial LOS in a pediatric population.
